Public Company Edition: There was just one initial public offering during the past two weeks, but another biotech-focused SPAC went public and Gingko Bioworks announced a high-value SPAC merger. Also, Insmed and Dynavax offerings led recent public company financings.

Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.

A financing round that was significantly oversubscribed by new and existing investors will help advance the Oxford-headquartered biotech's exosome therapeutics into the clinic and expand its technology platform.

Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.